Suppr超能文献

潜伏性结核感染治疗的十年创新:直接观察治疗中标准疗法与短程疗法的比较

[10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy].

作者信息

López G, Wood M, Ayesta F J

机构信息

Centro Penitenciario de Bilbao, Bilbao, España.

出版信息

Rev Esp Sanid Penit. 2011;13(1):3-14. doi: 10.4321/s1575-06202011000100002.

Abstract

OBJECTIVES

The main aim of the study is to compare the acceptance, adherence, tolerance and safety of short course therapies in comparison to a standard 9 month treatment for latent tuberculosis infection (LTBI) in directly observed therapy (DOT) and contrast this with previous results from a standard therapy in patient self-administered treatment.

MATERIALS AND METHODS

Retrospective longitudinal study carried out at a medium sized prison. Period of inclusion covers 10 years, from January 2000 to December 2009. The Centers for Disease Control and Prevention (CDC) inclusion and exclusion criteria were used, as well as the ones included in the Program for Tuberculosis Prevention and Control in the Prison Environment. 4 LTBI therapies according to the preference of the patient and possible interactions with other treatments were utilised. Therapy I consisted of isoniazid (H) in doses of 300 mg/day for 9 months (9H), therapy II with rifampicin for 2 months, twice a week, (2R2Z2) therapy III with rifampicin and isoniazid for 3 months (3RH) and therapy IV with rifampicin for four months (4R). Treatment was administered under strict DOT conditions by nursing staff.

RESULTS

902 patients were included, of which 810 accepted the treatment (89.90%), distributed as follows: 400 in the 9H therapy, and 410 with short course therapies (316 in the 2R2Z2, 82 in the 3RH therapy and 12 in the 4R therapy). 92 patients (10.20%) did not accept LTBI therapy, 271 patients (67.75%) concluded the LTBI treatment with 9H, and 314 (76.60%) with short courses. 232 patients (73.42%) concluded the 2R2Z2, 85.40% with the 3RH 70 therapy and 12 (100%) with the 4R treatment. 129 patients (32.25%) did not complete the LTBI 9H therapy (63 due to voluntary withdrawal, 35 due to adverse reactions, 26 for release or transfer, 2 for unknown reasons, 1 due to tuberculosis in a HIV-patient and 1 due to suicide). 96 patients (23.41%) did not conclude the short course therapies (36 due to voluntary withdrawal, 54 due to adverse reactions, 1 due to release or transfer, 3 for unknown reasons, 1 due to a psychotic episode, and 1 due to hepatitis of unknown aetiology). Significant differences could be discerned in the LTBI therapy conclusion rates when comparing the standard 9H and short course therapies. A greater, statistically significant, probability is observed with the short course therapies: p: 0.006; Odds Ration: 1.56 (LC95%: 1.14-2.12). This difference is a result of the 9H therapy presenting a greater number of voluntary withdrawals for no apparent reason (p: 0.002; OR: 2.03 [1.30-3.15]) and a greater number of withdrawals as a result of transfers to another prison or release (p<0.0001; OR 30.22 [4.07-224.29]), with no significant differences being found in withdrawals for adverse reactions between the 9H therapy and the short course treatments as a whole. The 2R2Z2 therapy shows a higher probability of withdrawals for adverse reactions (p: 0.006; OR: 1.87 [(1.21-2.88]) than the other therapies.

CONCLUSION

Greater acceptance of initiating therapy was observed in all the DOT therapies. The 3RH, 2R2Z2 and 4R short course therapies favoured better adherence, with significantly lower ratios of withdrawal than the 9H therapy for the treatment of latent tuberculosis infection. Tolerance and safety of the short course therapies was very similar to the standard 9H treatment, with a significantly higher percentage of adverse reactions in the 2R2Z2 therapy in comparison to others. Our data backs up the safety and adherence of a short course 3RH therapy in DOT for treating latent tuberculosis infection and its preferential use in the prison environment in comparison to isoniazid due to the greater number of patients concluding treatment. The administration of LBTI therapy in DOT achieves a high percentage of acceptance and conclusion of treatments in prison, significantly improving on the previous results in a cross-sectional study of the prison environment and others obtained at our centre in self-administered treatment.

摘要

目的

本研究的主要目的是比较短程疗法与标准9个月疗程治疗潜伏性结核感染(LTBI)在直接观察治疗(DOT)中的接受度、依从性、耐受性和安全性,并将其与患者自我管理治疗中标准疗法的先前结果进行对比。

材料与方法

在一所中等规模的监狱进行回顾性纵向研究。纳入期涵盖2000年1月至2009年12月的10年。采用美国疾病控制与预防中心(CDC)的纳入和排除标准以及监狱环境中结核病预防与控制项目所包含的标准。根据患者偏好及与其他治疗可能的相互作用,采用了4种LTBI疗法。疗法I为每日服用300mg异烟肼(H),疗程9个月(9H);疗法II为利福平治疗2个月,每周两次(2R2Z2);疗法III为利福平和异烟肼治疗3个月(3RH);疗法IV为利福平治疗4个月(4R)。治疗由护理人员在严格的DOT条件下进行。

结果

共纳入902例患者,其中810例接受了治疗(89.90%),分布如下:9H疗法400例,短程疗法410例(2R2Z2疗法316例,3RH疗法82例,4R疗法12例)。92例患者(10.20%)未接受LTBI治疗,271例患者(67.75%)完成了9H的LTBI治疗,314例(76.60%)完成了短程治疗。232例患者(73.42%)完成了2R2Z2疗法,3RH疗法为85.40%,4R疗法为100%(12例)。129例患者(32.25%)未完成9H的LTBI治疗(63例因自愿退出,35例因不良反应,26例因释放或转狱,2例原因不明,1例因HIV患者并发结核病,1例因自杀)。96例患者(23.41%)未完成短程治疗(36例因自愿退出,54例因不良反应,1例因释放或转狱,3例原因不明,1例因精神病发作,1例因病因不明的肝炎)。比较标准9H疗法和短程疗法时,LTBI治疗完成率存在显著差异。短程疗法的完成概率更高,具有统计学意义:p:0.006;优势比:1.56(95%可信区间:1.14 - 2.12)。这种差异是由于9H疗法出现了更多无明显原因的自愿退出(p:0.002;OR:2.03 [1.30 - 3.15])以及因转至另一监狱或释放导致的更多退出情况(p < 0.0001;OR 30.22 [4.07 - 224.29]),而9H疗法和整体短程治疗在因不良反应导致的退出方面未发现显著差异。2R2Z2疗法因不良反应导致退出的概率高于其他疗法(p:0.006;OR:1.87 [(1.21 - 2.88)])。

结论

在所有DOT疗法中,观察到开始治疗的接受度更高。3RH、2R2Z2和4R短程疗法有利于更好的依从性,与9H疗法相比,治疗潜伏性结核感染时退出率显著更低。短程疗法的耐受性和安全性与标准9H治疗非常相似,2R2Z2疗法的不良反应发生率明显高于其他疗法。我们的数据支持了在DOT中短程3RH疗法治疗潜伏性结核感染的安全性和依从性,并且由于完成治疗的患者数量更多,与异烟肼相比,其在监狱环境中更适合优先使用。在DOT中进行LBTI治疗在监狱中实现了高接受度和治疗完成率,显著优于之前在监狱环境横断面研究以及我们中心在自我管理治疗中获得的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验